All In Biotech

Drug Trial Radar · NCT05062902

A Novel Medical System for Quantitative Diagnosis and Personalized Precision Botulinum Neurotoxin Injection in Chronic Pelvic Pain Management

An Novel Medical System for Quantitative Diagnosis and Personalized Precision Botulinum Neurotoxin Injection in Chronic Pelvic Pain Management

Last checked: Nov 20, 2026Latest source record: Aug 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

46

Planned (sponsor's estimate)

Start

Sep 15, 2025

Primary completion

Aug 15, 2027

Study completion Dec 1, 2027

Sponsor

Lead sponsor
HillMed Inc.Industry
Sponsor type
Industry
Collaborators
Baylor College of Medicine; University of Houston
First posted
Sep 30, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Early phase 1
Allocation
Randomized
Model
Crossover
Masking
Double (investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate if it is possible to use intravaginal high-density surface electromyography to guide Botulinum neurotoxin (BoNT) injection to treat pelvic floor muscle overactivity that complicates Chronic Pelvic Pain (CPP).

Conditions

  • Interstitial Cystitis
  • Chronic Pain
  • Pelvic Floor; Relaxation
  • Pelvic Floor Disorders

Interventions

  • High Density Surface Electromyographic, precision botulinum neurotoxin injection guidance medical deviceDevice

    A personalized, precision botulinum neurotoxin injection guidance medical device, utilizing an intra-vaginal high-density surface EMG system to optimize the treatment outcomes in chronic pelvic pain (CPP) management.

  • Botulinum NeurotoxinDrug

    Botulinum neurotoxin will be injected into the pelvic floor muscles following either a standard template (standard injection arm), or guided using high-density surface EMG (guided arm).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Hypertonic metrics of the pelvic muscles defined by intra-vaginal surface EMGTime frame: Baseline
  2. Hypertonic metrics of the pelvic muscles defined by intra-vaginal surface EMGTime frame: 1-Month Post Injection
  3. Hypertonic metrics of the pelvic muscles defined by intra-vaginal surface EMGTime frame: 3-Months Post Injection

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Baylor College of Medicine

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.